2 weeks Ago By ABMN Staff
Cantor Fitzgerald upgraded shares of Verve Therapeutics ( NASDAQ:VERV – Free Report ) from a neutral rating to an overweight rating in a research report released on Tuesday, Marketbeat.com reports. Other equities analysts have also recently issued reports about the company.
Royal Bank of Canada cut their target price on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th.
William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Guggenheim reissued a “buy” rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. HC Wainwright raised their price target on shares of Verve Therapeutics from $15.
00 to $25.00 and gave the company a “buy” rating in a research report on Monday. Finally, Canaccord Genuity Group boosted their price objective on Verve Therapeutics from $32.
00 to $39.00 and gave the stock a “buy” rating in a report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.
com, the company currently has a consensus rating of “Buy” and a consensus price target of $25.75. Read Our Latest Report on VERV Verve Therapeutics Trading Up 1.
8 % Verve Therapeutics ( NASDAQ:VERV – Get Free Report ) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.
72) by $0.14. The business had revenue of $13.
08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.
23% and a negative net margin of 807.65%. Equities analysts predict that Verve Therapeutics will post -2.
49 earnings per share for the current fiscal year. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently added to or reduced their stakes in VERV. GAMMA Investing LLC increased its stake in Verve Therapeutics by 189.
7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock valued at $34,000 after buying an additional 3,964 shares during the last quarter. KFG Wealth Management LLC bought a new position in shares of Verve Therapeutics in the first quarter valued at approximately $46,000.
IFP Advisors Inc increased its position in shares of Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after acquiring an additional 8,237 shares during the last quarter.
BNP Paribas Financial Markets bought a new stake in Verve Therapeutics during the fourth quarter worth $50,000. Finally, Impact Partnership Wealth LLC purchased a new position in Verve Therapeutics in the fourth quarter worth $70,000. 97.
11% of the stock is currently owned by hedge funds and other institutional investors. Verve Therapeutics Company Profile ( Get Free Report ) Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Featured Articles Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
